Organization
3 public AI deployments across 3 use cases, Canada. Every number is quoted from its source.
Use case: AI for health insurance prior authorization and claims adjudication support
Canada · Insurance · 2026
In its first quarter 2026 report to shareholders, Manulife says it enhanced online claims processing for its Affinity health and dental business in Canada with AI driven document processing for the majority of claims that were processed manually, which improved processing speed and paid customers faster. No figures were published.
No outcome disclosed.
Use case: AI assistant for insurance brokers and agents
Canada · Insurance · 2025
Manulife's annual reports describe a generative AI sales tool in Singapore and Japan that drafts personalized engagement strategies for agents from customer needs, demographics and transaction history. By 2025 it had deployed GenAI sales enablement across nine markets and all four operating segments, with engagement insights, automated email drafting and real time coaching; in Hong Kong it launched AI Sales Pro for agents, and in Indonesia, Singapore and Japan AI assistants give agents faster access to product and policy information. In U.S. Retirement (part of its Global Wealth and Asset Management segment), Manulife says an AI sales enablement solution reduced time spent on information searches and tripled the number of sales opportunities compared with 2024.
No outcome disclosed.
Use case: AI summarization of medical evidence for life and health underwriting
Canada · Insurance · 2024
Manulife's 2024 annual report says generative AI in Singapore automates document digitization and summarization in underwriting, improving the accuracy of underwriting decisions and reducing processing time for policy applications, and that in the US it expanded the use of electronic health records and used generative AI to automate preliminary underwriting assessments. In 2025 it partnered with Munich Re Life US on alitheia, an AI driven risk assessment platform, raising the instant underwriting decision eligibility limit from US$3 million to US$5 million. No time or accuracy figures are disclosed.
No outcome disclosed.
